According to the latest report by IMARC Group, titled “Migraine Drugs Market Size: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” The global migraine drugs market size reached US$ 3.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 5.4 Billion by 2027, exhibiting a growth rate (CAGR) of 5.72% during 2022-2027. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the market in any form.

Industry Definition and Application:

Migraine drugs refer to medications that are used to reduce the severity of migraines and prevent future attacks. A migraine is a severe, neurological disease with a debilitating headache, characterized by an intense throbbing or pulsing in one area of the head. It is accompanied by sensitivity to light, sound and smell, visual disturbances such as auras, and nausea or vomiting. Migraine drugs do not cure migraines; instead, they treat or relieve these symptoms. There are certain blood pressure medications, as well as some antidepressants, anti-seizure drugs and herbals that are used to reduce the frequency of migraines.

Request Free Sample Report: https://www.imarcgroup.com/migraine-drugs-market/requestsample

Global Migraine Drugs Market Trends:

According to the Migraine Trust, migraine is the third most common disease globally, with more than 10% of people getting affected by the condition worldwide. This represents the primary factor that has increased the demand for migraine drugs across the globe. Apart from this, the rising healthcare expenditure and improving reimbursement policies for migraine medications are also acting as growth-inducing factors. Besides this, healthcare providers have made significant advancements in the diagnosis and treatment of migraine. A more advanced treatment modality with mechanism-based therapies, including supraorbital transcutaneous stimulation (STS) and transcranial magnetic stimulation, has been introduced as a preventive therapy for migraine. Additionally, there are many other drugs with novel mechanisms of action or new therapeutic targets, which are in different development stages.

Report Segmentation:

The report has segmented the market into the following categories:

Breakup by Treatment Type:

  • Abortive Treatment
  • Preventive Treatment

Breakup by Drug Type:

  • Triptans
  • Ergot Alkaloids
  • NSAIDs
  • Acetylcholine Inhibitors/ Neurotoxins
  • Ditans
  • CGRP mAbs
  • Others

Breakup by Route of Administration:

  • Oral
  • Injectable
  • Others

Breakup by Distribution Channel:

  • Hospital-Based Pharmacies
  • Retail Pharmacies
  • Others

Breakup by Region:

  • North America: (United States, Canada)
  • Asia Pacific: (China, Japan,India, South Korea, Australia, Indonesia, Others)
  • Europe: (Germany, France,United Kingdom, Italy, Spain, Russia, Others)
  • Latin America: (Brazil, Mexico, Others)
  • Middle East and Africa

Competitive Landscape Key Player:

  • Abbott Laboratories
  • Allergan Plc (Abbvie Inc.)
  • Amgen Inc.
  • AstraZeneca Plc
  • Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • Endo International Plc
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Limited.

Ask Analyst and Browse Full Report with TOC List of Figure: https://www.imarcgroup.com/request?type=report&id=2543&flag=C

Note: We are in the process of updating our reports. If you want to receive the latest research data covering the time period from 2023 to 2028, along with industry trends, market size, and competitive analysis, click on the request sample report. The team would be able to deliver the latest version of the report in a quick turnaround time.

If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high-technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us

IMARC Group
Email: sales@imarcgroup.com
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Address: 134 N 4th St. Brooklyn, NY 11249, USA
Follow us on Twitter: @imarcglobal